Understanding PD-L1 Assessment: Insights from Breast and Cervical Cancer Specimens

In this session, we will provide a comprehensive overview of PD-L1, including its significance in cancer immunotherapy, different assessment types, and explore different specimen types encountered in everyday practice.

Throughout the webinar, gain valuable insights into PD-L1 assessment methodologies and their application in breast and cervical cancer diagnostics. Real-life examples and case studies will be used to enhance understanding and facilitate interactive learning.

Don't miss this opportunity to deepen your understanding of PD-L1 assessment in breast and cervical cancer specimens. Register now to secure your spot!

Presenter: Dr. Philippe Taniere (Consultant, Histopathologist/Molecular Pathologist, University Hospitals Birmingham NHS Foundation Trust)

Dr. Taniere graduated in histopathology (MD) from the University of Lyon, France, in 1995. He obtained a PhD at the Unit of Molecular Carcinogenesis at the International Agency for Research on Cancer, Lyon in 2002.

Since October 2002, Dr. Taniere has been a consultant in histopathology at University Hospitals Birmingham (UHB) with an interest in gastrointestinal tract pathology, lung tumors, and soft tissue sarcomas.

Dr Taniere is the clinical service lead for Molecular Pathology at University Hospitals Birmingham. The Molecular Pathology Diagnostic Service (MPDS) comprises 60 scientists and technicians and performs over 35,000 tests each year. The service offers a wide range of analyses, including DNA sequencing in solid tumors and plasma (RT-PCR, pyrosequencing, Sanger sequencing, DNA/RNA-based NGS targeted panels), as well as microscopy-based technologies (immunohistochemistry and FISH).